BL
AVXL icon

Balentine LLC’s Anavex Life Sciences AVXL Stock Holding History

Balentine LLC’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,200
Closed -$115K – 185
2024
Q3 		$115K Buy
+20,200
New +$117K ﹤0.01% 160
2018
Q1 		– Sell
-280
Closed -$1K – 96
2017
Q4 		$1K Hold
280
– – ﹤0.01% 611
2017
Q3 		$1K Hold
280
– – ﹤0.01% 624
2017
Q2 		$1K Hold
280
– – ﹤0.01% 596
2017
Q1 		$2K Hold
280
– – ﹤0.01% 540
2016
Q4 		$1K Hold
280
– – ﹤0.01% 487
2016
Q3 		$1K Buy
+280
New +$1.18K ﹤0.01% 442

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Balentine LLC's AVXL Position: Q4 2024 in Review

Balentine LLC sold out of Anavex Life Sciences (AVXL) in Q4 2024, closing a stake of 20,200 shares — an estimated $115K sold.

Balentine LLC first reported a position in AVXL in Q3 2016 and held it in 7 quarters. The position peaked at $115K in Q3 2024. 168 funds tracked by Wall St. Rank hold AVXL as of Q4 2024.

  • Balentine LLC reported no remaining Anavex Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Balentine LLC sold 20,200 Anavex Life Sciences shares in Q4 2024, an estimated $115K.
  • Balentine LLC first reported a position in Anavex Life Sciences in Q3 2016 and held it in 7 quarters.
  • Balentine LLC's Anavex Life Sciences position peaked at $115K in Q3 2024.
  • 168 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2024.

Based on Balentine LLC's 13F filing for Q4 2024, filed 29 Jan 2025.